Fang Ni - 18 Nov 2021 Form 3 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Officer Title: Chief Business Officer and interim Chief Financial Officer
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol
BDTX
Transactions as of
18 Nov 2021
Net transactions value
$0
Form type
3
Filing time
29 Nov 2021, 20:23:48 UTC
Next filing
17 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BDTX Common Stock 44,026 18 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BDTX Stock Option (Right to Buy) 18 Nov 2021 Common Stock 120,000 $29.87 Direct F2
holding BDTX Stock Option (Right to Buy) 18 Nov 2021 Common Stock 55,000 $28.69 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 21,000 Restricted Stock Units ("RSUs") granted under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three equal annual installments with the first installment commencing on August 3, 2021, the one-year anniversary of the "vesting commencement date," subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F2 25% of the shares subject to this option vested and became exercisable on August 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter.
F3 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Officer Title: Chief Business Officer and interim Chief Financial Officer